DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)

Information source: Genentech, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Macular Edema; Retinal Vein Occlusion

Intervention: Ranibizumab 0.5 mg (Drug)

Phase: N/A

Status: Completed

Sponsored by: Genentech, Inc.

Official(s) and/or principal investigator(s):
Phillip Lai, M.D., Study Director, Affiliation: Genentech, Inc.

Summary

This is an open-label, multicenter, extension study of intravitreally administered ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g, NCT00379795) enrolled subjects with primary or recurrent Choroidal Neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g (NCT00056823)). The second cohort (reported here) enrolled subjects with macular edema secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018) or FVF4166g (NCT00485836)). Patients were enrolled within 14 days of completion of the previous study.

Clinical Details

Official title: An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Number of Participants With Ocular Adverse Events in the Study Eye

Number of Participants With Non-ocular Adverse Events

Secondary outcome:

Change From Baseline in the Best Corrected Visual Acuity (BCVA)

Change From Baseline in Central Foveal Thickness at Month 6 and Month 12

Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Signed informed consent form

- The 6-month treatment and 6-month observation phases (12 months total) of a

Genentech-sponsored ranibizumab study for RVO (FVF4165g or FVF4166g)

- Expectation by the investigator that the subject may potentially benefit from

intravitreal anti-vascular endothelial growth factor (VEGF) treatment Exclusion Criteria:

- History of intraocular surgery (including cataract extraction, scleral buckle, etc.)

within 1 month prior to Day 0 of this extension study

- Concurrent use of systemic anti-VEGF agents

- Use of RVO treatments not approved by the Food and Drug Administration (FDA) in the

study eye

- Use of intravitreal bevacizumab in the study eye and/or fellow eye

- Macular edema in the study eye due to other causes than RVO such as diabetes

- History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the

study eye

- History of idiopathic or autoimmune-associated uveitis in either eye

- Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 30 mmHg

despite treatment with antiglaucoma medication)

- Pregnancy or lactation

- Premenopausal women not using adequate contraception

- History of other disease, metabolic dysfunction, physical examination finding, or

clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk for treatment complications

- Current treatment for active systemic infection

- Inability to comply with study or follow-up procedures

Locations and Contacts

Additional Information

Starting date: July 2008
Last updated: December 5, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017